QIMA Lifesciences

QIMA Life Sciences is a specialized Contract Research Organization (CRO) and CDMO providing end-to-end research and testing services for the pharmaceutical, biotech, and cosmetic industries. The organization operates through a network of specialized laboratories, including entities such as QIMA Bioalternatives, QIMA Newtone, QIMA Monasterium, QIMA Skinpharma, and Oxiproteomics. Their scientific capabilities encompass in vitro, ex vivo, and clinical evaluation, utilizing advanced analytical platforms to support drug discovery, efficacy substantiation, and safety testing from early development stages through to clinical trials. By integrating multidisciplinary expertise in cellular and molecular pharmacology, dermatology, and image processing, they deliver customized, science-driven strategies designed to accelerate development timelines and optimize research outcomes for global clients.

These services are critical for partners seeking to substantiate product claims, improve the success rates of drug candidates, or navigate complex regulatory environments. QIMA Life Sciences leverages state-of-the-art facilities—including over 10,000 square meters of laboratory space and clinical infrastructure equipped for Phase I to IV trials—to provide robust, regulatory-aligned data. With nearly 30 years of experience and a team of over 600 professionals, the organization supports clients in making data-backed R&D decisions. Their commitment to innovation is evidenced by extensive scientific output, including hundreds of published works, which helps clients in the beauty, healthcare, and veterinary sectors ensure their products meet rigorous quality and performance standards.